• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Merck & Co (NY:MRK)

    112.16 +2.98 (+2.73%)
    Official Closing Price Updated: 7:00 PM EDT, May 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Merck & Co

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    What's going on in today's pre-market session: S&P500 movers ↗
    Via Chartmill
    News headline image
    MRK Q1 Deep Dive: Oncology Strength, New Launches, and Pipeline Milestones Define Quarter
    Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q1 CY2026, with sales up 4.9% year on year to $16.29 billion. The co... 
    Via StockStory
    Top S&P500 movers in Thursday's after hours session ↗
    Via Chartmill
    News headline image
    Merck (MRK) Q1 2026 Earnings Call Transcript ↗
    Merck (MRK) Q1 2026 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    Merck (NYSE:MRK) Q1 2026 Results Show Underlying Strength Despite Acquisition-Driven Loss ↗
    Via Chartmill
    Merck & Co. Inc. (NYSE:MRK) Offers a Durable Dividend Backed by Strong Earnings ↗
    Via Chartmill
    News headline image
    Merck (NYSE:MRK) Surprises With Q1 CY2026 Sales
    Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 4.9% year on year to $16.... 
    Via StockStory
    News headline image
    Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Merck (MRK) Q1 Earnings Report Preview: What To Look For
    Global pharmaceutical company Merck (NYSE:MRK) will be reporting results this Thursday before market open. Here’s what investors should know. Merck beat anal... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Merck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    3 Biotech Stocks That Could Benefit from the Patent Cliff ↗
    Via MarketBeat
    Topics Intellectual Property
    News headline image
    Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Q4 Earnings Roundup: Merck (NYSE:MRK) And The Rest Of The Branded Pharmaceuticals Segment
    Let’s dig into the relative performance of Merck (NYSE:MRK) and its peers as we unravel the now-completed Q4 branded pharmaceuticals earnings season. Looking... 
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Why Merck (MRK) Shares Are Trading Lower Today
    What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a... 
    Via StockStory
    Topics Government Intellectual Property
    Which S&P500 stocks are gapping on Tuesday? ↗
    Via Chartmill
    News headline image
    3 Reasons We Love Merck (MRK)
    Over the past six months, Merck has been a great trade, beating the S&P 500 by 32%. Its stock price has climbed to $118.94, representing a healthy 37.8% incr... 
    Via StockStory
    Topics Stocks Supply Chain
    News headline image
    Better Pharma Dividend Stock: Novartis vs. Merck ↗
    Both are great stocks to buy in the current environment, but which one is the better bet? 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Tech Powerhouse: S&P 500 Eyes 12.6% Growth as AI Revolution Enters Second Gear
    As the first-quarter earnings season of 2026 kicks off, Wall Street is bracing for a high-stakes performance that could determine the trajectory of the market for the remainder of the year. With the... 
    Via MarketMinute
    Topics Artificial Intelligence Earnings Economy
    News headline image
    The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)
    As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc.... 
    Via Finterra
    Topics Economy Initial Public Offering Intellectual Property
    News headline image
    1 Profitable Stock for Long-Term Investors and 2 Facing Challenges
    While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
    Via StockStory
    News headline image
    The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026
    As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an... 
    Via Finterra
    Topics Earnings Economy Intellectual Property
    News headline image
    Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
    From Daiichi Sankyo
    Via Business Wire
    News headline image
    1 Momentum Stock on Our Buy List and 2 We Question
    Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements... 
    Via StockStory
    News headline image
    Which Dividend Pharma Stock Should a Value Investor Choose Today? ↗
    Bristol Myers Squibb looks like a value buy, so long as its pipeline remains strong. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis
    In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total... 
    Via MarketMinute
    Topics Bonds
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Terns Therapeutics, Inc. (Nasdaq – TERN), Whitestone REIT (NYSE – WSR), Rallybio Corporation (Nasdaq – RLYB), Day One Biopharmaceuticals, Inc. (Nasdaq - DAWN)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue
    Today's Date: April 9, 2026 Introduction In the high-stakes arena of biotechnology, few companies have undergone a transformation as dramatic as ImmunityBio, Inc. (NASDAQ: IBRX). Long viewed by Wall... 
    Via Finterra
    Topics Economy World Trade
    News headline image
    Why Terns Pharmaceuticals Stock Rocked the Market in March ↗
    A large peer is snapping up the company in a premium-priced deal. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500. ↗
    Could this player be heading into a new era of growth? 
    Via The Motley Fool
    Topics Artificial Intelligence Economy Stocks
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.